1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

29 May 2024
Admin
News Article

Datopotamab Deruxtecan Demonstrates Clinically Significant Increase in Overall Survival

Datopotamab Deruxtecan Demonstrates Clinically Significant Increase in Overall Survival Compared to Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer

Overview

In the TROPION-Lung01 phase 3 trial, datopotamab deruxtecan (Dato-DXd) demonstrated promising overall survival (OS) trends compared to docetaxel in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had undergone at least one prior line of therapy. Although the OS results did not achieve statistical significance in the overall trial population, there was a notable improvement in OS observed specifically in patients with nonsquamous NSCLC, a subgroup where Dato-DXd exhibited clinically meaningful benefits over the current standard of care, docetaxel.

About Dato-DXd

Developed collaboratively by Daiichi Sankyo and AstraZeneca, Dato-DXd is an engineered antibody drug conjugate targeting TROP2, a protein commonly found in NSCLC tumors.
The drug showed statistically significant improvements in progression-free survival (PFS) and meaningful clinical benefits in nonsquamous NSCLC patients during earlier analyses. Safety-wise, Dato-DXd maintained a consistent profile with previous assessments, with fewer dose adjustments or discontinuations due to adverse events compared to docetaxel and no new safety concerns identified.

Significance of Dato-DXd in treating nonsquamous NSCLC

Dr. Ken Takeshita from Daiichi Sankyo emphasized the potential of Dato-DXd as a significant advancement in treating nonsquamous NSCLC, highlighting its notable improvements in OS, PFS, overall response rates, and duration of response compared to conventional chemotherapy.
He expressed intentions to expedite regulatory discussions to make Dato-DXd available to patients.
Similarly, Dr. Susan Galbraith from AstraZeneca underscored the significance of Dato-DXd's survival benefits, particularly in a treatment landscape where conventional options have been largely unchanged for some time.

These findings will be presented at upcoming medical conferences and will support regulatory submissions worldwide, including in the US and EU, for the treatment of adult patients with locally advanced or metastatic nonsquamous NSCLC who have received prior systemic therapy.

TROPION-Lung01

TROPION-Lung01, a global phase 3 trial, enrolled approximately 600 patients across various regions.
The trial's primary endpoints were PFS and OS, with key secondary endpoints including objective response rate, duration of response, and safety assessments.

NSCLC: A Significant Health Challange

With nearly 2.5 million new cases of lung cancer diagnosed globally each year, NSCLC remains a significant health challenge.
While advancements in immunotherapy and targeted therapies have improved outcomes in earlier lines of treatment, there remains a need for effective therapies for patients who progress after initial treatments.
Dato-DXd represents a promising candidate in this regard, with its potential to offer meaningful clinical benefits to patients with advanced nonsquamous NSCLC.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!